Compare DRIO & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DRIO | COCH |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Medical/Dental Instruments | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.6M | 49.7M |
| IPO Year | 2013 | N/A |
| Metric | DRIO | COCH |
|---|---|---|
| Price | $7.50 | $0.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $35.00 | $6.00 |
| AVG Volume (30 Days) | 5.5K | ★ 119.6K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1559.02 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $7,394,000.00 | N/A |
| Revenue This Year | $20.27 | $1.58 |
| Revenue Next Year | $47.58 | N/A |
| P/E Ratio | $6.25 | ★ N/A |
| Revenue Growth | ★ 43.02 | N/A |
| 52 Week Low | $0.38 | $0.36 |
| 52 Week High | $17.74 | $1.89 |
| Indicator | DRIO | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 53.82 |
| Support Level | $7.29 | $0.63 |
| Resistance Level | $9.46 | $0.73 |
| Average True Range (ATR) | 0.46 | 0.04 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 23.73 | 58.55 |
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.